Intravenous Drip of Somatostatin Followed by Restricted Fluid Resuscitation to Treat Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis

Objective. Liver cirrhosis is a common, often progressive, and usually fatal disorder. Upper gastrointestinal bleeding is a leading cause of death in patients with liver cirrhosis. The purpose of this study was to evaluate the effectiveness of somatostatin combined with restricted fluid resuscitatio...

Full description

Saved in:
Bibliographic Details
Published in:Evidence-based complementary and alternative medicine 2021, Vol.2021, p.6548479-6
Main Authors: He, Xuni, Dai, Zhuhua, Shi, Peina, Hong, Jiemin
Format: Article
Language:English
Subjects:
Bleeding
Blood pressure
Blood transfusions
Cirrhosis
Disease
Drug dosages
Erythrocytes
Esophagus
Evidence-based medicine
Fibrinogen
Gastroenterology
Heart rate
Hematemesis
Hematocrit
Hemoglobin
Hepatitis
Intravenous administration
Liver
Liver cirrhosis
Mortality
Patients
Platelets
Somatostatin
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. Liver cirrhosis is a common, often progressive, and usually fatal disorder. Upper gastrointestinal bleeding is a leading cause of death in patients with liver cirrhosis. The purpose of this study was to evaluate the effectiveness of somatostatin combined with restricted fluid resuscitation in the treatment of upper gastrointestinal bleeding in the patients with liver cirrhosis. Methods. From January 2018 to December 2020, 84 patients with liver cirrhosis complicated by upper gastrointestinal bleeding admitted to the Department of Gastroenterology of Ningbo Yinzhou No. 2 Hospital were selected as study participants. They were randomly assigned into the study group (n = 42) and control group (n = 42). All patients were given intravenous drip of somatostatin. The study group was supplemented with restricted fluid resuscitation therapy. The hemoglobin (Hb), platelet, fibrinogen, hematocrit, transfusion volume of red blood cells, hemostatic time, hemostatic rates in 0 h–24 h, 24 h–48 h, and >48 h, rebleeding rates, resuscitation rate, and incidence rates of complications were compared between the two groups 48 h after treatment. Results. It was found that the Hb, platelet, fibrinogen, and hematocrit were notably increased in the study group compared to the control group 48 h after treatment P
ISSN:1741-427X
1741-4288
DOI:10.1155/2021/6548479